Elecsys® Alzheimer’s Disease Testing Sites

 

Biomarkers to support early diagnosis of Alzheimer’s Disease
Alzheimer's Disease doesn't wait. Neither should a diagnosis.

Australian laboratories offering Elecsys® Alzheimer’s Disease testing:

New South Wales

Concord Hospital Diagnostic Pathology Unit - NSW Health Pathology

Dr Phoebe Stanford

Staff Specialist, Chemical Pathology

Ph: +61 2 9767 6663

Email: [email protected]

Tests offered

Abeta 1-42 CSF, phospho Tau 181 CSF, total tau CSF

Victoria

National Dementia Diagnostics Laboratory

A/Prof Qiao-Xin Li, PhD

Principal Research Fellow

Florey Institute 

The University of Melbourne

Email: [email protected]

www.florey.edu.au/national-dementia-diagnostics-laboratory

Tests offered

CSF testing: Abeta 1-42 , phospho Tau 181 , total Tau, NfL

Plasma/serum testing:  phospho Tau 181, NfL

Research testing: ptau 217 plasma, GFAP, NfL, Abeta 40 CSF

South Australia

Royal Adelaide Hospital / SA Pathology

Dr Penelope Coates

Clinical Director, Chemical Pathology 

Ph: +61 8 8222 3444

Email: [email protected]

www.sapathology.sa.gov.au

Tests offered

Abeta 1-42 CSF, phospho Tau 181 CSF, total tau CSF

Elecsys pTau 181 plasma testing availability

The Elecsys phospho Tau 181 plasma test is available at the Florey Institute’s National Dementia Diagnostics Laboratory (NDDL) in Melbourne Victoria.

Requests may be made through pathology providers Healius and Sonic pathology forms. Collection and transport of patient samples for the ptau 181 plasma test is facilitated via the Healius and Sonic pathology networks. 

Please contact your local Healius or Sonic lab for details.

Our first Roche Blood Based Biomarker dedicated to stratifying patients evaluated for Alzheimer's Disease: Elecsys® Phospho-Tau (181P) Plasma - A streamlined approach to diagnosis and care
The introduction of blood-based biomarkers like pTau 181 marks a significant step forward in addressing the challenges of the current Alzheimer's Disease diagnostic pathway.  This innovation aims to create a more efficient and accessible journey for patients.
 
Traditional methods for confirming amyloid pathology, such as positron emission tomography (PET) scans and cerebrospinal fluid (CSF) assessments, can be expensive, difficult to access, and invasive.  The Elecsys® pTau181 Plasma is set to change the landscape by providing a minimally invasive, blood-based solution.
pTau 181 plasma animated explainer